Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinopharm and China NT Form $33 Million Acquisition Company

publication date: Sep 12, 2013
Sinopharm and China NT Pharma Group will form a special purchase vehicle with capital of 200 million RMB ($33 million). The SPV will make acquisitions as a means of building a specialized vaccine and cold-chain drug distribution operation in the Shanghai area. China NT Pharma, like Sinopharm, is involved in drug distribution. Sinopharm will own 60% of the SPV and China NT will own the remaining 40%. More details....

Stock Symbols: (HK: 1099) (HK: 1011)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital